Active Biotech Delårsrapport januari – mars 2020

Kvartal 1 i korthetActive Biotech offentliggör ny inriktningPatent beviljat i Japan för användning av tasquinimod i multipelt myelomHändelser efter periodens utgångMed anledning av COVID-19-pandemin kommer det i samband med Årsstämman planerade investerarmötet att skjutas upp till en senare tidpunktEkonomisk översiktFör ytterligare information, vänligen kontakta:Rapporten finns även tillgänglig på Biotech är skyldigt att offentliggöra informationen i denna delårsrapport enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, den 23 april, 2020, kl. 08.30 CET. BilagaActive Biotech Delårsrapport januari – mars 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.